CoChat
Sign Up
Cited by 7Ovarian function and disordersDiabetes, Cardiovascular Risks, and LipoproteinsCerebral Venous Sinus Thrombosis

The LIPT-Study: On Risk Markers of Vascular Thrombosis in Polycystic Ovary Syndrome. A Randomized, Double-Blind, Placebo-Controlled Study of the Effect of Liraglutide

Open access
Malin Nylander, Signe Frossing·2015·Journal of Obesity & Weight Loss Therapy
DOI 10.4172/2165-7904.1000254
Open this paper in CoChat — free account

Abstract

Overweight and insulin resistance (IR) are central pathogenic features of the Polycystic Ovary Syndrome (PCOS), and weight loss is the main treatment option. PCOS is also associated with signs of a chronic inflammation, activation of the coagulation system, defect endothelial function and increased arterial stiffness, all regarded as risk factors or markers for the development of cardiovascular disease. These factors are not taken into account in the definition of the syndrome, which is based on the 3 Rotterdam criteria. An uncertainty of the clinical risk of cardiovascular disease (CVD) in these relatively young women has led to many studies on surrogate markers of CVD in PCOS, including the search for new markers with additional information of the arteriosclerotic burden in PCOS. GLP-1 analogues, originally developed for the treatment of diabetes, induce weight loss also in non-diabetic people. We therefore questioned whether treatment with the GLP-1 analogue Liraglutide to women with PCOS in doses used for diabetes could induce weight loss and improve IR and through this action, or independently, improve markers of vascular thrombosis in women with PCOS. Thus, 70 overweight and/or insulin resistant PCOS women were planned treated for 26 weeks in a placebo controlled randomized trial with the following effect parameters to be evaluated: Changes in Thrombin generation time, Adrenomedullin, Atrial natriuretic peptide, body fat composition (DEXA), liver fat content (MRI), BMI, IR, sex hormones and ovarian morphology. The protocol and the background for the study are brought in this report.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.4172/2165-7904.1000254

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • A power analysis for the secondary endpoint MR-proADM indicated that with a sample size of 42:21, an in-house s.d. of 0.03 nmol/L and a two-sided significance level of 5%, the study could detect a change in MR-proADM of 0.025 nmol/L (approximately 5% of baseline) with 90% power.

    “A power analysis of the secondary endpoint MR-proADM was performed before randomization as described (25). With a sample size of 42:21 (liraglutide:placebo), an in-house s.d. of 0.03 nmol/L and a two-sided significance level of 5%, we were able to detect a change in MR-proADM of 0.025 nmol/L (equal to approximately 5% of the baseline values) with a power of 90%.”

    From Effect of liraglutide on atrial natriuretic peptide, adrenomedullin, and copeptin in PCOS (2018) · cites this paper as [25]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Malin Nylander, S. F.
Venue
Journal of Obesity & Weight Loss Therapy
Publisher
OMICS Publishing Group
Published
2015
Volume
05
Issue
02
ISSN
2165-7904 (ISSN-L)
DOI
10.4172/2165-7904.1000254
OpenAlex
W2481340408
Cited by
7
References
34
Citations by year
2018: 1 · 2017: 3 · 2016: 3
FWCI
2.67
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
Journal of Obesity & Weight loss Therapy (publishedVersion, cc-by)
Topics
  • Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Neurology › Cerebral Venous Sinus Thrombosis
Keywords
polycystic ovary syndrome, liraglutide, GLP-1 receptor agonists, insulin resistance, weight loss, cardiovascular risk markers, vascular thrombosis, thrombin generation, adrenomedullin, atrial natriuretic peptide, endothelial function, arterial stiffness, overweight women, liver fat, sex hormones

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review